Leveraging our more than 20 years of gene therapy leadership.
uniQure is delivering on the promise of gene therapy — single treatments with potentially curative results.
We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with severe genetic diseases of the central nervous system (CNS) and liver, including clinical programs in hemophilia B and Huntington’s disease and preclinical candidates in Fabry disease, spinocerebellar ataxia Type 3, temporal lobe epilepsy, Alzheimer’s, Parkinson’s, and ALS.
Our pipeline of adeno-associated virus (AAV)-based gene therapies has been developed using an innovative technology platform, supported by industry-leading proprietary commercial-grade manufacturing capabilities.
Halleh Ghorashi, Jeroen Kluck and Hergen Spits winners Impact Award 2021!
NewsUvA’ most recent spinout SolarFoil aims to increase greenhouse productivity by optimizing sunlight to increase crop yields. In doing so, the use of SolarFoil aims to reduce the use of energy- hungry artificial lighting and make horticulture more sustainable. The team behind SolarFoil, professor Peter Schall and PhD Arnon Lesage of the UvA’ Institute of […]
NewsAmsterdamse Science & Innovation Awards 2021 voor digitale urineweegschaal, nanofolie en dyslexiespel voor kinderen In NEMO Amsterdam zijn voor de 15e keer de jaarlijkse Innovation Awards uitgereikt. De innovatieprijzen zijn een initiatief van de Innovation Exchange Amsterdam (IXA). IXA bekroont met de Awards vernieuwende ideeën om de samenleving te verbeteren van jonge wetenschappers, allemaal verbonden […]
News